BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002;20:1167-74. [PMID: 11870157 DOI: 10.1200/JCO.2002.20.5.1167] [Cited by in Crossref: 478] [Cited by in F6Publishing: 8] [Article Influence: 23.9] [Reference Citation Analysis]
Number Citing Articles
1 Wang SL, Liao Z, Liu H, Ajani J, Swisher S, Cox JD, Komaki R. Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer. World J Gastroenterol 2006; 12(34): 5501-5508 [PMID: 17006988 DOI: 10.3748/wjg.v12.i34.5501] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 23] [Article Influence: 1.9] [Reference Citation Analysis]
2 Jiang XJ, Song MQ, Xin YN, Gao YQ, Niu ZY, Tian ZB. Endoscopic stenting and concurrent chemoradiotherapy for advanced esophageal cancer: A case-control study. World J Gastroenterol 2012; 18(12): 1404-1409 [PMID: 22493556 DOI: 10.3748/wjg.v18.i12.1404] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
3 Zhang WZ, Chen JZ, Li DR, Chen ZJ, Guo H, Zhuang TT, Li DS, Zhou MZ, Chen CZ. Simultaneous modulated accelerated radiation therapy for esophageal cancer: A feasibility study. World J Gastroenterol 2014; 20(38): 13973-13980 [PMID: 25320535 DOI: 10.3748/wjg.v20.i38.13973] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
4 Matono S, Fujita H, Tanaka T, Mori N, Nagano T, Nishimura K, Hino H, Shirouzu K, Eto H, Ogo E, Yanagawa T. Salvage lymphadenectomy without esophagectomy is an option for recurrent or residual lymph nodes after definitive chemoradiotherapy for esophageal cancer. Esophagus 2014;11:197-203. [DOI: 10.1007/s10388-014-0430-z] [Cited by in Crossref: 7] [Article Influence: 0.9] [Reference Citation Analysis]
5 Fiore FD, Lecleire S, Rigal O, Galais MP, Soussan EB, David I, Paillot B, Jacob JH, Michel P. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12(26): 4185-4190 [PMID: 16830371 DOI: 10.3748/wjg.v12.i26.4185] [Cited by in CrossRef: 49] [Cited by in F6Publishing: 48] [Article Influence: 3.1] [Reference Citation Analysis]
6 Jeong Y, Kim JH. WITHDRAWN: Multimodality treatment for locally advanced esophageal cancers. Gastrointestinal Intervention 2014. [DOI: 10.1016/j.gii.2014.09.003] [Reference Citation Analysis]
7 Miura A, Honda M, Izumi Y, Kato T, Ryoutokuji T, Kuga G, Karasawa K, Momma K, Fujiwara J, Egashira H, Yoshida M. Induction chemotherapy followed by chemoradiotherapy for T4M0 esophageal cancer. Esophagus 2011;8:31-7. [DOI: 10.1007/s10388-011-0255-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
8 Villaflor VM, Allaix ME, Minsky B, Herbella FA, Patti MG. Multidisciplinary approach for patients with esophageal cancer. World J Gastroenterol 2012; 18(46): 6737-6746 [PMID: 23239911 DOI: 10.3748/wjg.v18.i46.6737] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 16] [Article Influence: 1.6] [Reference Citation Analysis]
9 Sugimura K, Motoori M, Yano M, Ishihara R, Hanaoka N, Miyoshi N, Akita H, Goto K, Kobayashi S, Takahashi H, Omori T, Noura S, Ohue M, Fujiwara Y, Sakon M. Endoscopic steroid injection reduced frequency of repeat dilation in patients with anastomotic stenosis after esophagectomy. Esophagus 2016;13:62-7. [DOI: 10.1007/s10388-015-0495-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
10 Meng MB, Jiang C, Tian LJ, Liu CL, Zhuang HQ, Chen ZJ, Song YC, Wang J, Pang QS, Zhao LJ, Yuan ZY, Wang P. Late course accelerated hyperfractionation radiotherapy for locally advanced esophageal squamous cell carcinoma. Thorac Cancer 2013;4:174-85. [PMID: 28920199 DOI: 10.1111/j.1759-7714.2012.00166.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
11 Boers J, Joldersma A, van Dalsen AD, Wiegman EM, Schenk BE, de Graaf JC, Pierik EGJM, Timmer PR, de Groot JWB. Intensified Neoadjuvant Chemoradiotherapy for Patients with Potentially Resectable Esophageal Cancer: A Retrospective Cohort Study. Ann Surg Oncol 2020;27:1520-8. [PMID: 31828691 DOI: 10.1245/s10434-019-08114-z] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
12 Liu WQ, Kang M, Yuan K. Prognosis of patients with esophageal carcinoma after radiotherapy: an analysis of 85 cases. Shijie Huaren Xiaohua Zazhi 2011; 19(26): 2772-2776 [DOI: 10.11569/wcjd.v19.i26.2772] [Reference Citation Analysis]
13 Tsuda T, Inaba H, Miyazaki A, Izawa N, Hirakawa M, Watanabe Y, Kitajima S, Hoshikawa Y, Gomi H, Kimura M, Itoh F. Prospective study of definitive chemoradiotherapy with S-1 and nedaplatin in patients with stage II/III (non-T4) esophageal cancer. Esophagus 2011;8:45-51. [DOI: 10.1007/s10388-011-0261-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
14 Wang YD, Lu N. Consensus and controversies on dose and target volume of three-dimensional conformal radiotherapy for esophageal carcinoma. Shijie Huaren Xiaohua Zazhi 2016; 24(34): 4531-4536 [DOI: 10.11569/wcjd.v24.i34.4531] [Reference Citation Analysis]
15 Almhanna K, Strosberg JR. Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol 2012; 18(40): 5679-5687 [PMID: 23155307 DOI: 10.3748/wjg.v18.i40.5679] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
16 Bedenne L, Vincent J, Jouve J. Is surgery always necessary in esophageal cancer? Esophagus 2011;8:3-7. [DOI: 10.1007/s10388-011-0258-8] [Cited by in Crossref: 3] [Article Influence: 0.3] [Reference Citation Analysis]